Seila Lorenzo-Herrero
Overview
Explore the profile of Seila Lorenzo-Herrero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perez-Rubio A, Mestre-Ferrandiz J, Lopez-Belmonte J, Diaz-Aguilo A, Lorenzo-Herrero S, Crespo C
BMC Infect Dis
. 2024 Aug;
24(1):779.
PMID: 39103777
Background: The objective of this study is to estimate the burden of selected immunization-preventable infectious diseases in Spain using the Burden of Communicable Diseases in Europe (BCoDE) methodology, as well...
2.
Sordo-Bahamonde C, Lorenzo-Herrero S, Granda-Diaz R, Martinez-Perez A, Aguilar-Garcia C, Rodrigo J, et al.
Mol Cancer
. 2023 Aug;
22(1):142.
PMID: 37649037
Recent introduction of monoclonal antibodies targeting immune checkpoints to harness antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic success of immune checkpoint blockade (ICB)-based therapies mainly relies on...
3.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Martinez-Perez A, Rodrigo J, Garcia-Pedrero J, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296876
Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under...
4.
Sordo-Bahamonde C, Lorenzo-Herrero S, Martinez-Perez A, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, et al.
Cancer Immunol Immunother
. 2023 Apr;
72(7):2529-2539.
PMID: 37041226
Patients with chronic lymphocytic leukemia (CLL) progressively develop marked immunosuppression, dampening innate and adaptive-driven antitumor responses. However, the underlying mechanisms promoting immune exhaustion are largely unknown. Herein, we provide new...
5.
Lorenzo-Herrero S, Sordo-Bahamonde C, Martinez-Perez A, Corte-Torres M, Fernandez-Vega I, Solis-Hernandez M, et al.
Cancer Sci
. 2022 Sep;
114(1):48-62.
PMID: 36082628
Glioblastoma stands as the most frequent primary brain tumor. Despite the multimodal therapy for glioblastoma patients, the survival rate is very low, highlighting the need for novel therapies that improve...
6.
Gonzalez-Rodriguez S, Lorenzo-Herrero S, Sordo-Bahamonde C, Hidalgo A, Gonzalez S, Menendez L, et al.
Life Sci
. 2022 Jan;
291:120302.
PMID: 34999112
Aims: To explore the mechanisms involved in the transformation of analgesia produced by low doses of CCL4 (pg/kg) to hyperalgesia when higher doses (ng/kg) are administered to mice. Main Methods:...
7.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, Lopez-Soto A, et al.
Cancers (Basel)
. 2021 Apr;
13(9).
PMID: 33925565
The inclusion of monoclonal antibodies targeting immune checkpoints such PD-1/PD-L1 or CTLA-4 has revolutionized the landscape of anti-cancer therapy. However, PD-1 and CTLA-4 blockade failed to achieve clinical benefit in...
8.
Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez-Rodriguez A, Payer A, Gonzalez-Garcia E, Lopez-Soto A, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33917094
Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as a powerful tool to...
9.
Costales P, Rios-Lombardia N, Lorenzo-Herrero S, Moris F, Gonzalez-Sabin J
Bioorg Chem
. 2021 Apr;
112:104859.
PMID: 33836453
A novel series of enantiopure naphthalimide-cycloalkanediamine conjugates were designed, synthetized and evaluated for in vitro cytotoxicity against human colon adenocarcinoma (LoVo), human lung adenocarcinoma (A549), human cervical carcinoma (Hela) and...
10.
Gonzalez-Rodriguez A, Payer A, Menendez-Suarez J, Sordo-Bahamonde C, Lorenzo-Herrero S, Zanabili J, et al.
J Clin Med
. 2020 Nov;
9(11).
PMID: 33213108
The correlation between progression and the genetic characteristics of Binet stage A patients with chronic lymphocytic leukemia (CLL) detected by whole exome sequencing (WES) was analyzed in 55 patients. The...